Vaccines Against Leishmaniosis in Dogs
Vaccine Composition | Vaccination Protocol | Antibody Kinetics in Initial Vaccination | Vaccine-Associated Interference With Serological Testing | Availability |
|---|---|---|---|---|
Recombinant chimeric protein Q No adjuvant | Initial SC dose Annual reinforcement | Peak: 14 days after initial vaccination Duration: basal levels at 180 days | No detection of vaccine antibodies by quantitative tests or rapid tests | Europe |
Recombinant A2 antigen of Leishmania donovani Saponin adjuvant | Three initial SC doses, with 21 days between consecutive doses Annual reinforcement | Peak: 21 days after second initial dose Duration: decrease after 6 months | Detection of vaccine antibodies with ELISA | Brazil |
DNA plasmid containing LACK gene No adjuvant | Two primary vaccination doses (intranasal),15-day interval One booster every 6 months | Not described | No detection of vaccine antibodies | Europe |
Adapted from Solano-Gallego L, Cardoso L, Pennisi MG, et al. Diagnostic challenges in the era of canine Leishmania infantum vaccines. Trends Parasitol. 2017; 33(9)706-717. doi:10.1016/j.pt.2017.06.004 | ||||